| Literature DB >> 32046183 |
Da-Hye Lee1,2, Jiyun Ahn1,2, Young-Jin Jang1, Hyo-Deok Seo1, Tae-Youl Ha1,2, Min Jung Kim1, Yang Hoon Huh3, Chang Hwa Jung1,2.
Abstract
Withania somnifera (WS), commonly known as ashwagandha, possesses diverse biological functions. WS root has mainly been used as an herbal medicine to treat anxiety and was recently reported to have an anti-obesity effect, however, the mechanisms underlying its action remain to be explored. We hypothesized that WS exerts its anti-obesity effect by enhancing energy expenditure through improving the mitochondrial function of brown/beige adipocytes and skeletal muscle. Male C57BL/6J mice were fed a high-fat diet (HFD) containing 0.25% or 0.5% WS 70% ethanol extract (WSE) for 10 weeks. WSE (0.5%) supplementation significantly suppressed the increases in body weight and serum lipids, and lipid accumulation in the liver and adipose tissue induced by HFD. WSE supplementation increased oxygen consumption and enhanced mitochondrial activity in brown fat and skeletal muscle in the HFD-fed mice. In addition, it promoted browning of subcutaneous fat by increasing mitochondrial uncoupling protein 1 (UCP1) expression. Withaferin A (WFA), a major compound of WS, enhanced the differentiation of pre-adipocytes into beige adipocytes and oxygen consumption in C2C12 murine myoblasts. These results suggest that WSE ameliorates diet-induced obesity by enhancing energy expenditure via promoting mitochondrial function in adipose tissue and skeletal muscle, and WFA is a key regulator in this function.Entities:
Keywords: Withania somnifera; anti-obesity; browning; energy expenditure; mitochondrial activity; withaferin A
Mesh:
Substances:
Year: 2020 PMID: 32046183 PMCID: PMC7071232 DOI: 10.3390/nu12020431
Source DB: PubMed Journal: Nutrients ISSN: 2072-6643 Impact factor: 5.717
Figure 1WSE prevents obesity by enhancing the oxygen consumption rate (OCR) in mice fed an HFD (high-fat diet). (A) Effect of WSE on mouse body weight during the 10 weeks experimental period. (B) Serum lipid levels. (C) VO2 levels throughout the light/dark cycle were analyzed by indirect calorimetry. The levels were normalized to body weight. (D) Area under the curve (AUC) of VO2. AUC was calculated using Prism software (ΔX*(Y1 + Y2)/2, X: Value of X axis, Y: Value of Y axis). (E) AUC of VCO2. (F) Energy expenditure was calculated based on the VO2 and VCO2 levels. (G) Rectal temperature was measured at room temperature. Data represent the mean ± SEM (n = 5). Difference between groups was evaluated by Tukey’s multiple comparison test. * p < 0.05; ** p < 0.01; *** p < 0.001 compared with the HFD group. N: Normal control diet.
Figure 2WSE enhances the mitochondrial function of brown adipose tissue (BAT) and the browning of subcutaneous adipose tissue (scWAT) in HFD-fed mice. (A) H&E staining and immunohistochemistry for the quantification of UCP1 (uncoupling protein 1) in BAT. (B) Protein expression of UCP1 in BAT. (C) Relative mRNA expression of BAT-specific genes (n = 5). (D) Expression of proteins involved in mitochondrial complexes III and IV in BAT. The subunits of mitochondrial complexes were detected using the total OXPHOS (oxidative phosphorylation) complex antibody cocktail. (E) Densitometry-based quantification data in (D), normalized to the level of VDAC (voltage-dependent anion channel). (F) Relative mRNA levels of the mitochondrial biogenesis-related genes, Tfam and Nrf1 (n = 5). (G) Citrate synthase activity in BAT (n = 5). (H) H&E staining and immunohistochemistry for quantification of UCP1 expression in scWAT. (I) Protein levels of UCP1 in scWAT. (J) mRNA expression of BAT-specific genes in scWAT (n = 5). Data represent the mean ± SEM. Difference between groups was evaluated by Tukey’s multiple comparison test. * p < 0.05; ** p < 0.01; *** p < 0.001 compared with the HFD group.
Figure 3WSE improves mitochondrial function in skeletal muscle. (A) Representative transmission electron microscopic images of the skeletal muscle. (B) Number of mitochondria per skeletal muscle area. (C) Relative mRNA levels of mitochondrial-related genes in skeletal muscle. (D) Citrate synthase activity in skeletal muscle. (E) Expression of protein involved in mitochondrial complexes III and IV in skeletal muscle, and densitometry-based quantification of the data, normalized to the level of VDAC (n = 3). (F) Activity of mitochondrial complexes III and IV in skeletal muscle. Data represent the mean ± SEM (n = 5). Difference between groups was evaluated by Tukey’s multiple comparison test. * p < 0.05; ** p < 0.01; *** p < 0.001 compared with the HFD group.
Figure 4Withaferin A (WFA) in WS enhances the differentiation into beige adipocytes and increases OCR. (A) LC-MS/MS analysis of WSE. (B) Contents of WFA and withanolide A (WNA) in 100 g of WSE. (C) UCP1 expression in differentiated 3T3-L1 beige adipocytes. (D) Expression of brown adipocyte-specific mRNA in differentiated 3T3-L1 beige adipocytes. (E) WFA increases protein expressions of UCP1 and Dio2 in beige adipocytes (n = 3). (F) WFA increases the OCR in C2C12 cells. C2C12 cells were treated with the indicated concentrations of WFA for 24 h. (G) Quantification of basal respiration, ATP production, maximal respiration, and spare capacity. Data represent mean ± SD of three independent experiments. Difference between groups was evaluated by Tukey’s multiple comparison test. * p < 0.05; ** p < 0.01, *** p < 0.001 compared with the vehicle group.